Title:
DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2023/134752
Kind Code:
A1
Abstract:
The present invention provides a diaryl compound as a tubulin/Src dual target inhibitor. The present invention also provides a diaryl compound represented by formula I, a tautomer, a stereoisomer, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof. The diaryl compound can be used as a dual target inhibitor against tubulin and Src kinase, and can also be used as a mono-target inhibitor against tubulin or Src kinase. The compound of the present invention can significantly inhibit the polymerization of tubulin monomers and cell proliferation.
Inventors:
ZHANG XUEJUN (CN)
ZANG YANG (CN)
YANG HUI (CN)
LEI SIJUN (CN)
WEI WENJUN (CN)
WU ZHIQIANG (CN)
LIU LIFEI (CN)
ZHANG XIN (CN)
LI LI'E (CN)
YANG JUN (CN)
ZANG YANG (CN)
YANG HUI (CN)
LEI SIJUN (CN)
WEI WENJUN (CN)
WU ZHIQIANG (CN)
LIU LIFEI (CN)
ZHANG XIN (CN)
LI LI'E (CN)
YANG JUN (CN)
Application Number:
PCT/CN2023/072143
Publication Date:
July 20, 2023
Filing Date:
January 13, 2023
Export Citation:
Assignee:
WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY (CN)
International Classes:
C07D413/12; A61K31/4427; A61K31/4436; A61P17/00; A61P35/00; C07D283/00; C07D295/04; C07D331/04; C07D401/12; C07D498/08; C07D498/10; C07F5/04
Foreign References:
| CN101595084A | 2009-12-02 | |||
| CN113461665A | 2021-10-01 | |||
| CN101687798A | 2010-03-31 |
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF:
Previous Patent: TUBULIN-SRC DUAL-TARGET INHIBITOR AND USE THEREOF
Next Patent: TUBULIN-SRC DUAL TARGET INHIBITOR
Next Patent: TUBULIN-SRC DUAL TARGET INHIBITOR